Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
Ngure K, Friedland BA, Szydlo DW, Roberts ST, Garcia M, Levy L, Akello CA, Reddy K, Palanee-Phillips T, Macdonald P, Siziba B, Soto-Torres L, Hosek S, Hillier SL, Nair G, Celum C, van der Straten A. Ngure K, et al. Among authors: soto torres l. PLoS One. 2023 Jun 23;18(6):e0287525. doi: 10.1371/journal.pone.0287525. eCollection 2023. PLoS One. 2023. PMID: 37352296 Free PMC article. Clinical Trial.
Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.
Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter III AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, Van Damme L, Celum CL. Tabet SR, et al. J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):476-83. doi: 10.1097/00126334-200308010-00008. J Acquir Immune Defic Syndr. 2003. PMID: 12869836 Clinical Trial.
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC. Keller MJ, et al. PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475. PLoS One. 2011. PMID: 21283552 Free PMC article. Clinical Trial.
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.
Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L; HIV Prevention Trials Network (HPTN) 035 Study Team. Abdool Karim SS, et al. AIDS. 2011 Apr 24;25(7):957-66. doi: 10.1097/QAD.0b013e32834541d9. AIDS. 2011. PMID: 21330907 Free PMC article. Clinical Trial.
Challenges of a hidden epidemic: HIV prevention among women in the United States.
Hodder SL, Justman J, Haley DF, Adimora AA, Fogel CI, Golin CE, O'Leary A, Soto-Torres L, Wingood G, El-Sadr WM; HIV Prevention Trials Network Domestic Prevention in Women Working Group. Hodder SL, et al. J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2(Suppl 2):S69-73. doi: 10.1097/QAI.0b013e3181fbbdf9. J Acquir Immune Defic Syndr. 2010. PMID: 21406990 Free PMC article.
88 results